ArticleJournal of pharmacological sciences2012
Urinary angiotensinogen as a novel early biomarker of intrarenal renin-angiotensin system activation in experimental type 1 diabetes.
Article in Journal of pharmacological sciences, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Hyperuricemia as an independent predictor of vascular complications and mortality in type 2 diabetes patients: a meta-analysis.PloS one · 2013Pooled it
- Isoflavones Inhibit Hydrogen Peroxide-Induced Angiotensinogen Secretion.International journal of molecular sciences · 2025Article
- Augmented Intrarenal and Urinary Angiotensinogen in Diabetic Nephropathy: The Role of Isoflavones.International journal of molecular sciences · 2025Review
- The roles of hydrogen sulfide in renal physiology and disease states.Renal failure · 2022Review
- Changes in Proximal Tubular Reabsorption Modulate Microvascular Regulation via the TGF System.International journal of molecular sciences · 2022Review
- Kidney Angiotensin in Cardiovascular Disease: Formation and Drug Targeting.Pharmacological reviews · 2022Review
- Sympathetic innervation of the mouse kidney and liver arising from prevertebral ganglia.American journal of physiology. Regulatory, integrative and comparative physiology · 2021Article
- α-Ketoglutarate Upregulates Collecting Duct (Pro)renin Receptor Expression, Tubular Angiotensin II Formation, and NaFrontiers in cardiovascular medicine · 2021Article
- Blockade of sodium-glucose cotransporter 2 suppresses high glucose-induced angiotensinogen augmentation in renal proximal tubular cells.American journal of physiology. Renal physiology · 2020Article
- Advanced Glycation End Products Stimulate Angiotensinogen Production in Renal Proximal Tubular Cells.The American journal of the medical sciences · 2019Article
- Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus.American journal of nephrology · 2019Article
- Increased urinary angiotensin converting enzyme 2 and neprilysin in patients with type 2 diabetes.American journal of physiology. Renal physiology · 2018Article
- Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2017Article
- Circadian rhythm of blood pressure and the renin-angiotensin system in the kidney.Hypertension research : official journal of the Japanese Society of Hypertension · 2017Review
- High glucose augments angiotensinogen in human renal proximal tubular cells through hepatocyte nuclear factor-5.PloS one · 2017Article
- Relationship between blood pressure variability and renal activity of the renin-angiotensin system.Journal of human hypertension · 2016Article
- Urinary Biomarkers in the Assessment of Early Diabetic Nephropathy.Journal of diabetes research · 2016Review
- Evaluation of kidney dysfunction and angiotensinogen as an early novel biomarker of intrauterine growth restricted offspring rats.Pediatric research · 2015Article
- Circulating and intrarenal renin-angiotensin systems in healthy men and nonpregnant women.Physiological reports · 2015Article
- Role of stimulated intrarenal angiotensinogen in hypertension.Therapeutic advances in cardiovascular disease · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Urinary excretion of albumin (UAlb) is used clinically as a marker of diabetic nephropathy (DN). Although DN was thought to be a unidirectional process, recent studies demonstrated that a large proportion of patients diagnosed with DN reverted to normoalbuminuria. Moreover, despite the normoalbuminuria, one-third of them exhibited reduced renal function even during the microalbuminuric stage. This study was performed to investigate whether urinary angiotensinogen (UAGT) level may serve as a useful marker of the early stage of experimental type 1 diabetes (T1DM). T1DM was induced by a single intraperitoneal injection of streptozotocin. Control mice were injected with citrate buffer. Two days after streptozotocin injection, half of the mice received continuous insulin treatment. Our data showed that UAlb excretion was increased 6 days after streptozotocin injection compared to controls, whereas UAGT excretion was increased at an earlier time point. These increases were reversed by insulin treatment. The UAGT to UAlb ratio was increased in diabetic mice compared to control mice. Furthermore, the increased AGT expression in the kidneys was observed in diabetic mice. These data suggest that UAGT might be useful as a novel early biomarker of activation of the renin-angiotensin system in experimental type 1 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.